Company Overview of Afexa Life Sciences Inc.
Afexa Life Sciences Inc., a health-sciences and technology company, engages in the discovery, development, and commercialization of natural health products for disease prevention and health maintenance in the United States and Canada. The company’s products include COLD-FX, which is designed to prevent and treat colds and flu by strengthening the immune system; CELL-FX, a natural product that helps relieve symptoms of bone and joint pain, and helps in the formation of connective tissue; IMMUNITY-FX, a product that strengthens and supports the immune system; and REMEMBER-FX, a natural health product intended to help restore mental alertness or wakefulness when experiencing fatigue or drowsine...
Edmonton, AB T6N 1G1
Founded in 1992
Key Executives for Afexa Life Sciences Inc.
Chief Executive Officer, President and Director
Co-Founder and Chief Scientific officer
Chief Marketing Officer and Senior Vice President of Sales
Senior Director of Investor Relations and Corporate Secretary
Chief Legal Officer and Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2017.
Afexa Life Sciences Inc. Key Developments
Judge Tosses Lawsuit over Cold-fX Claims
Nov 17 16
A judge has tossed out a unique class-action lawsuit that alleged the makers of one of natural-health product misled customers about the remedy's cold-fighting benefits. Justice Janice Dillon of the Supreme Court of British Columbia refused to 'certify' the suit, ruling on November 16, 2016, there was no evidence a group of people had a common grievance against the manufacturer of Cold-fX, as class-action law requires. Cold-fX was developed by Alberta-based Afexa Life Sciences, which was bought by Quebec's Valeant Pharmaceuticals Inc. in 2011. The suit charged that until recent years the firm claimed Cold-fX could bring 'immediate relief' to cold and flu symptoms, despite a lack of evidence. In fact, a company-funded study disclosed as part of the case found that it did no better than a placebo for that purpose. Some scientific evidence suggests that Cold-fX helps slightly reduce the number or severity of viruses in users who take the product daily for two to six months. The B.C. case was unusual among health-product class actions, charging not that the ginseng-based pills caused physical harm, but that their benefits were misrepresented. Dillon did not comment on whether the Cold-fX marketers had misled consumers, but said there was no evidence of a class of people who felt aggrieved - beyond Don Harrison, the 'representative' plaintiff. And it's unclear if even he was swayed by the allegedly misleading promotion.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries